Mojca Matičič
Datos Biográficos
| ID | 8760403 |
|---|---|
| NOMBRE | Mojca Matičič |
| NOMBRES | Mojca |
| APELLIDO | Matičič |
| FIRMA | MATICIC M |
| AFILIACIONES | Ljubljana University Medical Centre |
| ORCID | 0000-0003-4261-0424 |
| VERIFICADO | Sí |
| TOTAL DE OBRAS | 4 |
| TOTAL DE CITAS | 0 |
| TOTAL COMO AUTOR | 4 |
| TOTAL COMO EDITOR | 0 |
| PRIMER AÑO DE PUBLICACIÓN | 2017 |
| AÑO MÁS RECIENTE DE PUBLICACIÓN | 2024 |
| ÍNDICE H | 0 |
How far are we? Assessing progress in hepatitis C response towards the WHO 2030 elimination goals by the civil society monitoring in 25 European countries, period 2020 to 2023
BACKGROUND: With the advent of direct acting antivirals (DAAs) the World Health Organisation (WHO) adopted global strategy to eliminate hepatitis C virus (HCV) infection by 2030. In Europe, people who inject drugs (PWID) account for the majority of new cases, however testing and treatment remain suboptimal. The aim was to monitor progress in HCV policy and cascade-of-care for PWID, led by the civil society organisations (CSO) that provide harm re…
Monitoring progress towards elimination of hepatitis B and C in the EU/EEA
This paper presents data on selected indicators to show progress towards elimination goals and targets for hepatitis B and hepatitis C in the 31 countries of the European Union (EU) and European Economic Area (EEA). A monitoring system was developed by the European Centre for Disease Prevention and Control, which combined newly collected data from EU/EEA countries along with relevant data from existing sources. Data for 2017 were collected from t…
The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries
BACKGROUND: People who inject drugs (PWID) account for the majority of new cases of hepatitis C virus (HCV) infection in Europe; however, HCV testing, and treatment for PWID remain suboptimal. With the advent of direct acting antivirals (DAAs) the World Health Organization (WHO) adopted a strategy to eliminate HCV as public health threat by 2030. To achieve this, key policies for PWID must be implemented and HCV continuum of care needs to be moni…
Restrictions on access to direct-acting antivirals for people who inject drugs
Sin obras prominentes en esta página.
Restrictions on access to direct-acting antivirals for people who inject drugs
The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries
BACKGROUND: People who inject drugs (PWID) account for the majority of new cases of hepatitis C virus (HCV) infection in Europe; however, HCV testing, and treatment for PWID remain suboptimal. With the advent of direct acting antivirals (DAAs) the World Health Organization (WHO) adopted a strategy to eliminate HCV as public health threat by 2030. To achieve this, key policies for PWID must be implemented and HCV continuum of care needs to be moni…
Monitoring progress towards elimination of hepatitis B and C in the EU/EEA
This paper presents data on selected indicators to show progress towards elimination goals and targets for hepatitis B and hepatitis C in the 31 countries of the European Union (EU) and European Economic Area (EEA). A monitoring system was developed by the European Centre for Disease Prevention and Control, which combined newly collected data from EU/EEA countries along with relevant data from existing sources. Data for 2017 were collected from t…
How far are we? Assessing progress in hepatitis C response towards the WHO 2030 elimination goals by the civil society monitoring in 25 European countries, period 2020 to 2023
BACKGROUND: With the advent of direct acting antivirals (DAAs) the World Health Organisation (WHO) adopted global strategy to eliminate hepatitis C virus (HCV) infection by 2030. In Europe, people who inject drugs (PWID) account for the majority of new cases, however testing and treatment remain suboptimal. The aim was to monitor progress in HCV policy and cascade-of-care for PWID, led by the civil society organisations (CSO) that provide harm re…
Harm reduction (4 obras) · Hepatitis B Virus Studies (4 obras) · Hepatitis C virus research (4 obras) · Medicine (4 obras) · Environmental health (3 obras) · Harm (3 obras) · Health care (3 obras) · Hepatitis C (3 obras) · HIV, Drug Use, Sexual Risk (3 obras) · Political science (3 obras)